|Articles|April 1, 2020
- Pharmaceutical Executive-04-01-2020
- Volume 40
- Issue 4
Pharmaceutical Executive, April 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
HBA's Woman of the Year 2020: A Motivated Missionover 6 years ago
Doubling Down on D&Iover 6 years ago
COVID-19 Ripple Effects for Pharmaover 6 years ago
Prescribing Patterns: How to Get Ahead of the Trendsover 6 years ago
There’s No Easing the Price-vs.-Value Debateover 6 years ago
Payer Perspectives on Gene Therapy Reimbursementover 6 years ago
Covid-19 Pandemic Thrusts Biopharma R&D to Forefrontover 6 years ago
Transforming the CIO Role to Embrace Digital Healthover 6 years ago
Country Report: The Czech RepublicAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
3
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
4
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
5